HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outpatient therapy for febrile neutropenia.

AbstractPURPOSE OF REVIEW:
The management of febrile neutropenia has evolved significantly with the development of risk stratification and recognition of the efficacy of oral antibiotics in low-risk patients. There remains uncertainty concerning the need for hospitalization and role of early hospital discharge. We review recent evidence in this field and identify outstanding issues for future research.
RECENT FINDINGS:
Studies have confirmed the utility of the MASCC risk index. Preliminary findings suggest that early hospital discharge is feasible in low-risk patients with solid tumours and lymphomas, at least in specialist centres. Median hospital stays may be reduced to 48 h with no increase in serious medical complications. Readmission rates remain low.
SUMMARY:
All patients with febrile neutropenia should undergo risk stratification on admission, and low-risk patients should be considered eligible for combination oral antibiotics from the outset. Those patients who show signs of fever resolution and subjective improvement are eligible for early discharge. More research is required with regard to patients with haematological malignancies and/or receiving prophylactic antibiotics, and in the development of factors predictive of successful early discharge. Further data are required regarding whether strategies involving early discharge can be safely implemented at centres outside those which have pioneered these approaches.
AuthorsHelen Innes, Ernie Marshall
JournalCurrent opinion in oncology (Curr Opin Oncol) Vol. 19 Issue 4 Pg. 294-8 (Jul 2007) ISSN: 1040-8746 [Print] United States
PMID17545790 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
  • Antineoplastic Agents
Topics
  • Aftercare
  • Ambulatory Care
  • Anti-Bacterial Agents (administration & dosage)
  • Antineoplastic Agents (adverse effects)
  • Humans
  • Length of Stay
  • Neoplasms (drug therapy)
  • Neutropenia (chemically induced, drug therapy)
  • Prognosis
  • Risk Assessment
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: